Regional · UK & Ireland

MHRA statements, read directly

Regional › UK & Ireland NHS MHRA personal import

Solved Pinned

Solved by s.okonkwo in post #2

the opening post is right about the mechanism and I think understates the practical bit. Importing for personal use: importing a prescription-only medicine without a prescription is not lawful. Material sold as research-use-only is not a licensed medicine regardless of content.

Jump to the accepted answer →

v.milanoviTL3Regular4 Sep 2025#1

MHRA statements, read directly Writing it up because I had to work it out twice and would rather nobody else did.

A coverage question with the paperwork detail included, since that is what determines the answer.

Denial received, with a stated reason. My reading of the reason is that it tells me exactly what to submit next, which is the useful thing about a well-written denial.

Before I spend a week on it: is my reading of the stated criterion correct, and is there a documented precedent for this specific ground?

47 likes 11mo

s.okonkwoTL2 Moderator Solution9 Sep 2025#2

the opening post is right about the mechanism and I think understates the practical bit.

Importing for personal use: importing a prescription-only medicine without a prescription is not lawful. Material sold as research-use-only is not a licensed medicine regardless of content.

12 likes 11mo

g.haalandTL3Regular13 Sep 2025#3

Supply and shortage resilience: both UK and Ireland sourced primarily from European suppliers until recent disruptions. Domestic availability and pricing changed.

1 like 10mo

to.vargaTL2 Moderator16 Sep 2025#4

Ireland: the Health Products Regulatory Authority implements EU framework. Prescription-only. Reimbursement for weight management has been more restrictive than for diabetes. Private prescription at full cost is usual for weight management.

0 likes 10mo

JFitzgibbonTL2Member19 Sep 2025#5

s.okonkwo, post #2: the opening post is right about the mechanism and I think understates the practical bit. Importing for personal use: importing a prescription-only medicine without a prescription is not lawful. Material sold as research-use-only is not a licensed medicine regardless of content. Go to post

MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.

18 likes in reply to #2 10mo

s.beaulieuTL2 Moderator21 Sep 2025#6

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

7 likes 10mo

a.salcedoTL3Regular24 Sep 2025#7

Coming back to post #5, because the follow-up matters more than the original answer.

Private prescribing is legal and widespread, including through remote consultation. Pharmacies must satisfy themselves that a prescription is clinically appropriate. Expect to be asked for measurements and history.

0 likes 10mo

n.nakamuraTL2 Moderator27 Sep 2025#8

s.beaulieu, post #6: For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use. Go to post

NHS access has been restricted by commissioning criteria, not by licensing. Specialist weight-management services in many areas require prior weight-loss attempts, BMI thresholds, or other specific criteria.

0 likes in reply to #6 10mo

s.duarteTL2 Moderator29 Sep 2025#9

Compounding pharmacies: UK allows compounding under specific conditions when a licensed product is unavailable. That is not a front-line option but becomes relevant during shortages.

0 likes 10mo

a.sorensenTL2 Moderator2 Oct 2025#10

g.haaland, post #3: Supply and shortage resilience: both UK and Ireland sourced primarily from European suppliers until recent disruptions. Domestic availability and pricing changed. Go to post

Cross-border arrangements: some people source from other EU countries. Rules on import for personal use are changing post-Brexit. Current status requires checking with UKVI.

24 likes in reply to #3 10mo

il.dumitruTL2 Moderator4 Oct 2025 · edited#11

Occupational health screening: some UK occupations require medical checks. Disclosure of weight-loss medication might be relevant to employment screening; understand your obligations.

14 likes 10mo

g.haalandTL3Regular6 Oct 2025#12

v.milanovi, post #1: MHRA statements, read directly Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what determines the answer. Denial received, with a stated reason. My reading of the reason is that it tells me exactly what to submit next, which is the… Go to post

29 likes in reply to #1 10mo

e.coelhoTL2 Moderator9 Oct 2025#13

to.varga, post #4: Ireland: the Health Products Regulatory Authority implements EU framework. Prescription-only. Reimbursement for weight management has been more restrictive than for diabetes. Private prescription at full cost is usual for weight management. Go to post

Picking up post #10: that is the part I would want checked first.

Occupational health screening: some UK occupations require medical checks. Disclosure of weight-loss medication might be relevant to employment screening; understand your obligations.

0 likes in reply to #4 10mo

f.abrahamsenTL211 Oct 2025#14

Collapsed as off-topic by two members at trust level 3 or above

Coming back to post #12, because the follow-up matters more than the original answer.

MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.

ka.haddadTL2 Moderator13 Oct 2025#15

Compounding pharmacies: UK allows compounding under specific conditions when a licensed product is unavailable. That is not a front-line option but becomes relevant during shortages.

9 likes 9mo

a.salcedoTL3Regular15 Oct 2025#16

g.haaland, post #3: Supply and shortage resilience: both UK and Ireland sourced primarily from European suppliers until recent disruptions. Domestic availability and pricing changed. Go to post

Cross-border arrangements: some people source from other EU countries. Rules on import for personal use are changing post-Brexit. Current status requires checking with UKVI.

21 likes in reply to #3 9mo

m.yilmazTL2 Moderator17 Oct 2025#17

s.beaulieu, post #6: For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use. Go to post

This follows post #14 rather than contradicting it.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

0 likes in reply to #6 9mo

g.ibarraTL2 Moderator19 Oct 2025#18

Supply and shortage resilience: both UK and Ireland sourced primarily from European suppliers until recent disruptions. Domestic availability and pricing changed.

2 likes 9mo

s.cardosoTL2 Moderator21 Oct 2025#19

post #18 answers the question as asked. The question underneath it is different.

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

28 likes in reply to #1 9mo

j.dahlbergTL2 Moderator23 Oct 2025 · edited#20

JFitzgibbon, post #5: MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs. Go to post

On post #16 — agreed on the reasoning, with one qualification.

0 likes in reply to #5 9mo

an.kirchnerTL2 Moderator26 Oct 2025#21

Importing for personal use: importing a prescription-only medicine without a prescription is not lawful. Material sold as research-use-only is not a licensed medicine regardless of content.

20 likes 9mo

erratum_fileTL3Regular28 Oct 2025#22

Regional variation in NHS: access varies dramatically by region depending on local commissioning decisions and specialist service availability. Postcode determines access risk.

9 likes 9mo

s.perrinTL2 Moderator29 Oct 2025#23

2 likes 9mo

glossary_checkTL2Member31 Oct 2025 · edited#24

j.dahlberg, post #20: On post #16 — agreed on the reasoning, with one qualification. NHS access has been restricted by commissioning criteria, not by licensing. Specialist weight-management services in many areas require prior weight-loss attempts, BMI thresholds, or other specific criteria. Go to post

This follows post #21 rather than contradicting it.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

0 likes in reply to #20 9mo

s.kravchenkoTL2 Moderator2 Nov 2025#25

On post #21 — agreed on the reasoning, with one qualification.

Regional variation in NHS: access varies dramatically by region depending on local commissioning decisions and specialist service availability. Postcode determines access risk.

14 likes 9mo

cohort_notesTL2Member4 Nov 2025#26

Importing for personal use: importing a prescription-only medicine without a prescription is not lawful. Material sold as research-use-only is not a licensed medicine regardless of content.

5 likes 9mo

f.espinozaTL26 Nov 2025#27

Collapsed as off-topic by two members at trust level 3 or above

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

gradient_fileTL2Member8 Nov 2025#28

0 likes in reply to #20 9mo

m.almeidaTL2 Moderator10 Nov 2025#29

Worth separating two things that post #25 runs together.

MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.

9 likes 9mo

a.kowalczykTL2Regular12 Nov 2025#30

post #29 is right about the mechanism and I think understates the practical bit.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

2 likes 8mo

Sponsored PeptideMeter — peptide analytics and supplier verificationPurity analysis and structured supplier verification, published as dated records rather than scores. Referenced throughout our sourcing documentation.View analytics →